Everolimus 10 mg

DRUG4 trials

Sponsors

Novartis Pharmaceuticals, Banaras Hindu University, Fudan University, Forward Pharmaceuticals Co., Ltd.

Conditions

Advanced Breast CancerBreast CancerBreast Cancer Stage IBreast Cancer Stage IIER+ Breast CancerGallbladder CancerIslet Cell CarcinomaLocally Advanced Breast Cancer (LABC)

Phase 1

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

RecruitingNCT07002177

Forward Pharmaceuticals Co., Ltd.Breast Cancer Stage I, Breast Cancer Stage II, ER+ Breast Cancer +2

Start: 2025-06-01End: 2028-11-01Target: 196Updated: 2026-01-07

Phase 2

Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy

CompletedNCT00363051

Novartis PharmaceuticalsIslet Cell Carcinoma, Neuroendocrine Carcinoma, Neuroendocrine Tumor +1

Start: 2006-06-30End: 2012-04-30Updated: 2013-05-10

Addition of Everolimus to Standard of Care in Carcinoma Gallbladder

RecruitingNCT05833815

Banaras Hindu UniversityGallbladder Cancer

Start: 2022-11-01End: 2024-12-30Target: 56Updated: 2024-08-13

Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer

RecruitingNCT05949541

Fudan UniversityAdvanced Breast Cancer, Breast Cancer

Start: 2023-07-26End: 2028-01-31Target: 265Updated: 2024-02-08